A new paradigm for TB drug development is needed—one that focuses on developing not just drugs but entire drug regimens.
The Critical Path to TB Drug Regimens (CPTR) works to tackle the challenges facing TB drug development. This includes gaining support for a paradigm of drug development that enables promising combinations of drugs to be tested and developed together to create entirely new multi-drug treatments. This approach is expected to reduce the time it takes to develop an innovative regimen from decades to years. CPTR is made possible by unprecedented collaboration among pharma companies and strong commitments from public and private partners around the world. More >
TBA-354 is the first potential tuberculosis drug to advance toPhase 1 trial in six years TB Alliance has announced the start of the first human trial of a new tuberculosis (TB) drug candidate, designated TBA-354. It is the first new TB drug candidate to begin a Phase 1 clinical trial since 2009. “There is a
26 January 2015 – Tucson, Arizona, United States – Recognizing an international need for a centralized, standardized data resource for globally diverse genomic and other clinically relevant tuberculosis data, the Critical Path to TB Drug Regimens (CPTR) initiative has begun development and implementation of a Rapid Drug Susceptibility Test (RDST) data-sharing platform in partnership with
These stories link to the WHO's Working Group on New TB Drugs